Tuberculosis
Conditions
Brief summary
Assess sensitivity and specificity of two nucleic acid amplification tests, namely Epistem Genedrive® and MolbioTruenat™ in raw sputum compared to the WHO-endorsed GeneXpert® MTB/RIF assay using a gold standard of four cultures
Detailed description
* Estimate the accuracy of the Epistem Genedrive® and MolbioTruenat™ in raw sputum and in sputum pellets. * Assess the operational feasibility of Epistem Genedrive® and MolbioTruenat™ * Determine and compare costs between the Epistem Genedrive®, MolbioTruenat™, and Xpert MTB/RIF tests
Interventions
OTHEREpistem Genedrive® and MolBio Truenat™
S1 will undergo direct smear and Epistem Genedrive® (optional for phase 2\*) testing, before being homogenized with glass beads and split into three portions for testing with Epistem Genedrive®, MolBio Truenat™ and GeneXpert MTB/Rif® respectively. S2 and S3 will be randomized as to the order of testing using Epistem Genedrive® and MolBio Truenat™.
Sponsors
Boston Medical Center
Johns Hopkins University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* • Clinical suspicion of pulmonary TB (including cough ≥2 weeks and at least 1 other symptom typical of TB); * Age 18 years or above; * Willingness to have a study follow-up visit, if necessary, approximately two months after enrollment * Willingness to provide 3 sputum specimens at enrollment * Provision of informed consent.
Exclusion criteria
* • Receipt of ≥48 cumulative hours OR three or more doses of anti-TB treatment (defined as combination anti-TB therapy intended to treat active TB) within 60 days prior to completion of sputum collection; * Inability to provide informed consent (e.g. mentally impaired) * Enrolled individuals who do not provide a first sputum sample of ≥ 2ml and a second and third sputum sample of ≥ 1ml each will be classified as early exclusions.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Non-inferiority of tests | 4 months | Non-inferiority of Epistem Genedrive® MTB iD Test and MolBio Truenat™ TB Assay to GeneXpert MTB/RIF using a non-inferiority margin of 5% for sensitivity in smear-positive, culture-positive; 7% for overall C+ sensitivity; and 3% for specificity in smear-negative, culture-negatives |
| Sensitivity and specificity of Epistem Genedrive® MTB iD | 4 months | Sensitivity and specificity of Epistem Genedrive® MTB iD Test on raw sputum before homogenization, homogenized raw sputum and sputum pellet against a gold standard of concentrated smear and four cultures. |
| Sensitivity and specificity of MolBio Truenat™ TB Assay | 4 months | Sensitivity and specificity of MolBio Truenat™ TB Assay on homogenized raw sputum and sputum pellet against a gold standard of concentrated smear and four cultures. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Failure rate for the Epistem Genedrive® system assay and for the MolBio Truenat™ assay | 10 months | Failure rate for the Epistem Genedrive® system assay and for the MolBio Truenat™ assay, expressed as the proportion of tests that require repeating due to an indeterminate or uninterpretable initial result (separately and together for tests performed on raw sputum and sputum pellet |
| Cost-comparison between assays | 10 months | A cost-comparison between assays assessing the cost per sample run incorporating all costs involved in transport, equipment, reagents, personnel, etc. will be performed. |
| Training needs for each assay | 10 months | Training needs for each assay assessed objectively by number of hours of training, number of runs required, and successful completion of a proficiency assessment by trainees; training needs also will be assessed subjectively by the trainers and by user questionnaires |
| Operational feasibility | 10 months | Operational feasibility will be assessed according to the infrastructure required to support each test, the robustness of the reagents and equipment (any breakdowns, storage requirements or contamination events), and the time it takes to run each test; |
Countries
United States
Outcome results
None listed